1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
SENATE BILL 860 By: Weaver
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to the Uniform Controlled Dangerous
7
Substances Act; amending 63 O.S. 2021, Section 2-204,
8
as last amended by Section 3, Chapter 308, O.S.L.
8
2024 (63 O.S. Supp. 2024, Section 2-204), which
9
relates to Schedule I substances; adding certain
9
substance to Schedule I; and providing an effective
10
date.
10
11
11
12
12
13
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
13
14
SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-204, as
14
15
last amended by Section 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
15
16
2024, Section 2-204), is amended to read as follows:
16
17
Section 2-204. The controlled substances listed in this section
17
18
are included in Schedule I and include any material, compound,
18
19
mixture, or preparation that contains any quantity of the following
19
20
hallucinogenic substances, their salts, isomers, and salts of
20
21
isomers, unless specifically excepted, when the existence of these
21
22
salts, isomers, and salts of isomers is possible within the specific
22
23
chemical designation.
23
24
24
Req. No. 566 Page 1

1
A. Any of the following opiates including their isomers,
1
2
esters, ethers, salts, and salts of isomers, esters, and ethers,
2
3
unless specifically excepted, when the existence of these isomers,
3
4
esters, ethers, and salts is possible within the specific chemical
4
5
designation:
5
6
1. Acetylmethadol;
6
7
2. Allylprodine;
7
8
3. Alphacetylmethadol;
8
9
4. Alphameprodine;
9
10
5. Alphamethadol;
10
11
6. Benzethidine;
11
12
7. Betacetylmethadol;
12
13
8. Betameprodine;
13
14
9. Betamethadol;
14
15
10. Betaprodine;
15
16
11. Clonitazene;
16
17
12. Dextromoramide;
17
18
13. Dextrorphan (except its methyl ether);
18
19
14. Diampromide;
19
20
15. Diethylthiambutene;
20
21
16. Dimenoxadol;
21
22
17. Dimepheptanol;
22
23
18. Dimethylthiambutene;
23
24
19. Dioxaphetyl butyrate;
24
Req. No. 566 Page 2

1
20. Dipipanone;
1
2
21. Ethylmethylthiambutene;
2
3
22. Etonitazene;
3
4
23. Etoxeridine;
4
5
24. Furethidine;
5
6
25. Hydroxypethidine;
6
7
26. Isotonitazene;
7
8
27. Ketobemidone;
8
9
28. Levomoramide;
9
10
29. Levophenacylmorphan;
10
11
30. Metonitazene;
11
12
31. Morpheridine;
12
13
32. N-desethyl isotonitazene;
13
14
33. N-pyrrolidino protonitazene;
14
15
34. Noracymethadol;
15
16
35. Norlevorphanol;
16
17
36. Normethadone;
17
18
37. Norpipanone;
18
19
38. Phenadoxone;
19
20
39. Phenampromide;
20
21
40. Phenomorphan;
21
22
41. Phenoperidine;
22
23
42. Piritramide;
23
24
43. Proheptazine;
24
Req. No. 566 Page 3

1
44. Properidine;
1
2
45. Protonitazene;
2
3
46. Racemoramide; or
3
4
47. Trimeperidine.
4
5
B. Any of the following opium derivatives, their salts,
5
6
isomers, and salts of isomers, unless specifically excepted, when
6
7
the existence of these salts, isomers, and salts of isomers is
7
8
possible within the specific chemical designation:
8
9
1. Acetorphine;
9
10
2. Acetyldihydrocodeine;
10
11
3. Benzylmorphine;
11
12
4. Codeine methylbromide;
12
13
5. Codeine-N-Oxide;
13
14
6. Cyprenorphine;
14
15
7. Desomorphine;
15
16
8. Dihydromorphine;
16
17
9. Etorphine;
17
18
10. Heroin;
18
19
11. Hydromorphinol;
19
20
12. Methyldesorphine;
20
21
13. Methylhydromorphine;
21
22
14. Morphine methylbromide;
22
23
15. Morphine methylsulfonate;
23
24
16. Morphine-N-Oxide;
24
Req. No. 566 Page 4

1
17. Myrophine;
1
2
18. Nicocodeine;
2
3
19. Nicomorphine;
3
4
20. Normorphine;
4
5
21. Phoclodine;
5
6
22. Thebacon;
6
7
23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
7
8
(Acetyl fentanyl);
8
9
24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
9
10
(Crotonyl fentanyl);
10
11
25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
11
12
furancarboxamide (Furanyl fentanyl);
12
13
26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
13
14
27. N-(1-phenethylpiperidin-4-yl)-N-
14
15
phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
15
16
28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
16
17
(Butyrl fentanyl).
17
18
C. Any material, compound, mixture, or preparation which
18
19
contains any quantity of the following hallucinogenic substances,
19
20
their salts, isomers, and salts of isomers, unless specifically
20
21
excepted, when the existence of these salts, isomers, and salts of
21
22
isomers is possible within the specific chemical designation:
22
23
1. Methcathinone;
23
24
2. 3, 4-methylenedioxy amphetamine;
24
Req. No. 566 Page 5

1
3. 3, 4-methylenedioxy methamphetamine;
1
2
4. 5-methoxy-3, 4-methylenedioxy amphetamine;
2
3
5. 3, 4, 5-trimethoxy amphetamine;
3
4
6. Bufotenine;
4
5
7. Diethyltryptamine;
5
6
8. Dimethyltryptamine;
6
7
9. 4-methyl-2, 5-dimethoxyamphetamine;
7
8
10. Ibogaine;
8
9
11. Lysergic acid diethylamide;
9
10
12. Marijuana;
10
11
13. Mescaline;
11
12
14. N-benzylpiperazine;
12
13
15. N-ethyl-3-piperidyl benzilate;
13
14
16. N-methyl-3-piperidyl benzilate;
14
15
17. Psilocybin;
15
16
18. Psilocyn;
16
17
19. 2, 5 dimethoxyamphetamine;
17
18
20. 4 Bromo-2, 5-dimethoxyamphetamine;
18
19
21. 4 methoxyamphetamine;
19
20
22. Cyclohexamine;
20
21
23. Salvia Divinorum;
21
22
24. Salvinorin A;
22
23
23
24
24
Req. No. 566 Page 6

1
25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
1
2
thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
2
3
TPCP, TCP;
3
4
26. Phencyclidine (PCP);
4
5
27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
5
6
Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
6
7
28. 1-(3-trifluoromethylphenyl) piperazine;
7
8
29. Flunitrazepam;
8
9
30. B-hydroxy-amphetamine;
9
10
31. B-ketoamphetamine;
10
11
32. 2,5-dimethoxy-4-nitroamphetamine;
11
12
33. 2,5-dimethoxy-4-bromophenethylamine;
12
13
34. 2,5-dimethoxy-4-chlorophenethylamine;
13
14
35. 2,5-dimethoxy-4-iodoamphetamine;
14
15
36. 2,5-dimethoxy-4-iodophenethylamine;
15
16
37. 2,5-dimethoxy-4-methylphenethylamine;
16
17
38. 2,5-dimethoxy-4-ethylphenethylamine;
17
18
39. 2,5-dimethoxy-4-fluorophenethylamine;
18
19
40. 2,5-dimethoxy-4-nitrophenethylamine;
19
20
41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
20
21
42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
21
22
43. 2,5-dimethoxy-4-propylthio-phenethylamine;
22
23
44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
23
24
45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
24
Req. No. 566 Page 7

1
46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
1
2
47. 5-methoxy-N, N-dimethyltryptamine;
2
3
48. N-methyltryptamine;
3
4
49. A-ethyltryptamine;
4
5
50. A-methyltryptamine;
5
6
51. N, N-diethyltryptamine;
6
7
52. N, N-diisopropyltryptamine;
7
8
53. N, N-dipropyltryptamine;
8
9
54. 5-methoxy-a-methyltryptamine;
9
10
55. 4-hydroxy-N, N-diethyltryptamine;
10
11
56. 4-hydroxy-N, N-diisopropyltryptamine;
11
12
57. 5-methoxy-N, N-diisopropyltryptamine;
12
13
58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
13
14
59. 3,4-Methylenedioxymethcathinone (Methylone);
14
15
60. 3,4-Methylenedioxypyrovalerone (MDPV);
15
16
61. 3-Methylmethcathinone (Metaphedrone);
16
17
62. 4-Methylmethcathinone (Mephedrone);
17
18
63. 4-methoxymethcathinone;
18
19
64. 4-Fluoromethcathinone;
19
20
65. 3-Fluoromethcathinone;
20
21
66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
21
22
67. 2,5-Dimethoxy-4-chloroamphetamine;
22
23
68. 4-Methylethcathinone;
23
24
69. Pyrovalerone;
24
Req. No. 566 Page 8

1
70. N,N-diallyl-5-methoxytryptamine;
1
2
71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
2
3
72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
3
4
73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
4
5
74. Alpha-Pyrrolidinopentiophenone;
5
6
75. 4-Fluoroamphetamine;
6
7
76. Pentedrone;
7
8
77. 4’-Methyl-a-pyrrolidinohexaphenone;
8
9
78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
9
10
79. 2,5-dimethoxyphenethylamine;
10
11
80. 1,4-Dibenzylpiperazine;
11
12
81. N,N-Dimethylamphetamine;
12
13
82. 4-Fluoromethamphetamine;
13
14
83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
14
15
(25C-NBOMe);
15
16
84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
16
17
(25I-NBOMe);
17
18
85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
18
19
(25B-NBOMe);
19
20
86. 1-(4-Fluorophenyl)piperazine;
20
21
87. Methoxetamine;
21
22
88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
22
23
methylbenzamide;
23
24
89. N-ethyl hexadrone;
24
Req. No. 566 Page 9

1
90. Isopropyl-U-47700;
1
2
91. Para-fluorobutyrl fentanyl;
2
3
92. Para-fluorofentanyl (pFF);
3
4
93. Fluoro isobutryrl fentanyl;
4
5
94. 3-Hydroxy Phencyclidine (PCP);
5
6
95. 3-methoxy Phencyclidine (PCP);
6
7
96. Flualprazolam; or
7
8
97. Flubromazolam.
8
9
D. Unless specifically excepted or unless listed in a different
9
10
schedule, any material, compound, mixture, or preparation which
10
11
contains any quantity of the following substances having stimulant
11
12
or depressant effect on the central nervous system:
12
13
1. Fenethylline;
13
14
2. Mecloqualone;
14
15
3. N-ethylamphetamine;
15
16
4. Methaqualone;
16
17
5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
17
18
hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
18
19
oxybate, and sodium oxybutyrate;
19
20
6. Gamma-Butyrolactone (GBL) as packaged, marketed,
20
21
manufactured or promoted for human consumption, with the exception
21
22
of legitimate food additive and manufacturing purposes;
22
23
23
24
24
Req. No. 566 Page 10

1
7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
1
2
manufactured for human consumption, with the exception of legitimate
2
3
food additive and manufacturing purposes;
3
4
8. Gamma Valerolactone (GVL) as packaged, marketed, or
4
5
manufactured for human consumption, with the exception of legitimate
5
6
food additive and manufacturing purposes;
6
7
9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
7
8
manufactured, or promoted for human consumption with the exception
8
9
of legitimate manufacturing purposes; or
9
10
10. N-ethylpentylone.
10
11
E. 1. The following industrial uses of Gamma-Butyrolactone,
11
12
Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
12
13
excluded from all schedules of controlled substances under this
13
14
title:
14
15
a. pesticides,
15
16
b. photochemical etching,
16
17
c. electrolytes of small batteries or capacitors,
17
18
d. viscosity modifiers in polyurethane,
18
19
e. surface etching of metal coated plastics,
19
20
f. organic paint disbursements for water soluble inks,
20
21
g. pH regulators in the dyeing of wool and polyamide
21
22
fibers,
22
23
h. foundry chemistry as a catalyst during curing,
23
24
24
Req. No. 566 Page 11

1
i. curing agents in many coating systems based on
1
2
urethanes and amides,
2
3
j. additives and flavoring agents in food, confectionary,
3
4
and beverage products,
4
5
k. synthetic fiber and clothing production,
5
6
l. tetrahydrofuran production,
6
7
m. gamma butyrolactone production,
7
8
n. polybutylene terephthalate resin production,
8
9
o. polyester raw materials for polyurethane elastomers
9
10
and foams,
10
11
p. coating resin raw material, and
11
12
q. as an intermediate in the manufacture of other
12
13
chemicals and pharmaceuticals.
13
14
2. At the request of any person, the Director of the Oklahoma
14
15
State Bureau of Narcotics and Dangerous Drugs Control may exempt any
15
16
other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
16
17
Gamma Valerolactone, or 1,4 Butanediol from being included as a
17
18
Schedule I controlled substance if such product is labeled,
18
19
marketed, manufactured, and distributed for legitimate industrial
19
20
use in a manner that reduces or eliminates the likelihood of abuse.
20
21
3. In making a determination regarding an industrial product,
21
22
the Director, after notice and hearing, shall consider the
22
23
following:
23
24
a. the history and current pattern of abuse,
24
Req. No. 566 Page 12

1
b. the name and labeling of the product,
1
2
c. the intended manner of distribution, advertising, and
2
3
promotion of the product, and
3
4
d. other factors as may be relevant to and consistent
4
5
with the public health and safety.
5
6
4. The hearing shall be held in accordance with the procedures
6
7
of the Administrative Procedures Act.
7
8
F. Any material, compound, mixture, or preparation, whether
8
9
produced directly or indirectly from a substance of vegetable origin
9
10
or independently by means of chemical synthesis, or by a combination
10
11
of extraction and chemical synthesis, that contains any quantity of
11
12
the following substances, or that contains any of their salts,
12
13
isomers, and salts of isomers when the existence of these salts,
13
14
isomers, and salts of isomers is possible within the specific
14
15
chemical designation:
15
16
1. JWH-004;
16
17
2. JWH-007;
17
18
3. JWH-009;
18
19
4. JWH-015;
19
20
5. JWH-016;
20
21
6. JWH-018;
21
22
7. JWH-019;
22
23
8. JWH-020;
23
24
9. JWH-030;
24
Req. No. 566 Page 13

1
10. JWH-046;
1
2
11. JWH-047;
2
3
12. JWH-048;
3
4
13. JWH-049;
4
5
14. JWH-050;
5
6
15. JWH-070;
6
7
16. JWH-071;
7
8
17. JWH-072;
8
9
18. JWH-073;
9
10
19. JWH-076;
10
11
20. JWH-079;
11
12
21. JWH-080;
12
13
22. JWH-081;
13
14
23. JWH-082;
14
15
24. JWH-094;
15
16
25. JWH-096;
16
17
26. JWH-098;
17
18
27. JWH-116;
18
19
28. JWH-120;
19
20
29. JWH-122;
20
21
30. JWH-145;
21
22
31. JWH-146;
22
23
32. JWH-147;
23
24
33. JWH-148;
24
Req. No. 566 Page 14

1
34. JWH-149;
1
2
35. JWH-150;
2
3
36. JWH-156;
3
4
37. JWH-167;
4
5
38. JWH-175;
5
6
39. JWH-180;
6
7
40. JWH-181;
7
8
41. JWH-182;
8
9
42. JWH-184;
9
10
43. JWH-185;
10
11
44. JWH-189;
11
12
45. JWH-192;
12
13
46. JWH-193;
13
14
47. JWH-194;
14
15
48. JWH-195;
15
16
49. JWH-196;
16
17
50. JWH-197;
17
18
51. JWH-198;
18
19
52. JWH-199;
19
20
53. JWH-200;
20
21
54. JWH-201;
21
22
55. JWH-202;
22
23
56. JWH-203;
23
24
57. JWH-204;
24
Req. No. 566 Page 15

1
58. JWH-205;
1
2
59. JWH-206;
2
3
60. JWH-207;
3
4
61. JWH-208;
4
5
62. JWH-209;
5
6
63. JWH-210;
6
7
64. JWH-211;
7
8
65. JWH-212;
8
9
66. JWH-213;
9
10
67. JWH-234;
10
11
68. JWH-235;
11
12
69. JWH-236;
12
13
70. JWH-237;
13
14
71. JWH-239;
14
15
72. JWH-240;
15
16
73. JWH-241;
16
17
74. JWH-242;
17
18
75. JWH-243;
18
19
76. JWH-244;
19
20
77. JWH-245;
20
21
78. JWH-246;
21
22
79. JWH-248;
22
23
80. JWH-249;
23
24
81. JWH-250;
24
Req. No. 566 Page 16

1
82. JWH-251;
1
2
83. JWH-252;
2
3
84. JWH-253;
3
4
85. JWH-262;
4
5
86. JWH-292;
5
6
87. JWH-293;
6
7
88. JWH-302;
7
8
89. JWH-303;
8
9
90. JWH-304;
9
10
91. JWH-305;
10
11
92. JWH-306;
11
12
93. JWH-307;
12
13
94. JWH-308;
13
14
95. JWH-311;
14
15
96. JWH-312;
15
16
97. JWH-313;
16
17
98. JWH-314;
17
18
99. JWH-315;
18
19
100. JWH-316;
19
20
101. JWH-346;
20
21
102. JWH-348;
21
22
103. JWH-363;
22
23
104. JWH-364;
23
24
105. JWH-365;
24
Req. No. 566 Page 17

1
106. JWH-367;
1
2
107. JWH-368;
2
3
108. JWH-369;
3
4
109. JWH-370;
4
5
110. JWH-371;
5
6
111. JWH-373;
6
7
112. JWH-386;
7
8
113. JWH-387;
8
9
114. JWH-392;
9
10
115. JWH-394;
10
11
116. JWH-395;
11
12
117. JWH-397;
12
13
118. JWH-398;
13
14
119. JWH-399;
14
15
120. JWH-400;
15
16
121. JWH-412;
16
17
122. JWH-413;
17
18
123. JWH-414;
18
19
124. JWH-415;
19
20
125. CP-55, 940;
20
21
126. CP-47, 497;
21
22
127. HU-210;
22
23
128. HU-211;
23
24
129. WIN-55, 212-2;
24
Req. No. 566 Page 18

1
130. AM-2201;
1
2
131. AM-2233;
2
3
132. JWH-018 adamantyl-carboxamide;
3
4
133. AKB48;
4
5
134. JWH-122 N-(4-pentenyl)analog;
5
6
135. MAM2201;
6
7
136. URB597;
7
8
137. URB602;
8
9
138. URB754;
9
10
139. UR144;
10
11
140. XLR11;
11
12
141. A-796,260;
12
13
142. STS-135;
13
14
143. AB-FUBINACA;
14
15
144. AB-PINACA;
15
16
145. PB-22;
16
17
146. AKB48 N-5-Fluorpentyl;
17
18
147. AM1248;
18
19
148. FUB-PB-22;
19
20
149. ADB-FUBINACA;
20
21
150. BB-22;
21
22
151. 5-Fluoro PB-22; or
22
23
152. 5-Fluoro AKB-48.
23
24
24
Req. No. 566 Page 19

1
G. In addition to those substances listed in subsection F of
1
2
this section, unless specifically excepted or unless listed in
2
3
another schedule, any material, compound, mixture, or preparation
3
4
which contains any quantity of a synthetic cannabinoid found to be
4
5
in any of the following chemical groups:
5
6
1. Naphthoylindoles: any compound containing a 3-(1-
6
7
naphthoyl)indole structure with or without substitution at the
7
8
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
8
9
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
9
10
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
10
11
2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
11
12
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
12
13
halophenyl group, whether or not further substituted on the indole
13
14
ring to any extent, and whether or not substituted on the naphthyl
14
15
ring to any extent. Naphthoylindoles include, but are not limited
15
16
to:
16
17
a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
17
18
200),
18
19
b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
19
20
c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
20
21
d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
21
22
e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
22
23
f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
23
24
g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
24
Req. No. 566 Page 20

1
h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
1
2
i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
2
3
j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
3
4
k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
4
5
l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
5
6
m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
6
7
(JWH-098),
7
8
n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
8
9
o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
9
10
naphthoyl)indole (AM-1220),
10
11
p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
11
12
(MAM-2201), or
12
13
q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
13
14
2. Naphthylmethylindoles: any compound containing a 1H-indol-
14
15
3-yl-(1-naphthyl)methane structure with or without substitution at
15
16
the nitrogen atom of the indole ring by an alkyl, haloalkyl,
16
17
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
17
18
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
18
19
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
19
20
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
20
21
phenyl, or halophenyl group, whether or not further substituted on
21
22
the indole ring to any extent, and whether or not substituted on the
22
23
naphthyl ring to any extent. Naphthylmethylindoles include, but are
23
24
not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);
24
Req. No. 566 Page 21

1
3. Naphthoylpyrroles: any compound containing a 3-(1-
1
2
naphthoyl)pyrrole structure with or without substitution at the
2
3
nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
3
4
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
4
5
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
5
6
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
6
7
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
7
8
phenyl, or halophenyl group, whether or not further substituted on
8
9
the pyrrole ring to any extent, and whether or not substituted on
9
10
the naphthyl group to any extent. Naphthoylpyrroles include, but
10
11
are not limited to:
11
12
a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
12
13
b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
13
14
(JWH-370),
14
15
c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
15
16
d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);
16
17
4. Naphthylideneindenes: any compound containing a 1-(1-
17
18
naphthylmethylene)indene structure with or without substitution at
18
19
the 3-position of the indene ring by an alkyl, haloalkyl,
19
20
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
20
21
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
21
22
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
22
23
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
23
24
phenyl, or halophenyl group, whether or not further substituted on
24
Req. No. 566 Page 22

1
the indene group to any extent, and whether or not substituted on
1
2
the naphthyl group to any extent. Naphthylmethylindenes include,
2
3
but are not limited to, (1-[(3-pentyl)-1H-inden-1-
3
4
ylidene)methyl]naphthalene (JWH-176);
4
5
5. Phenylacetylindoles: any compound containing a 3-
5
6
phenylacetylindole structure with or without substitution at the
6
7
nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
7
8
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
8
9
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
9
10
2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
10
11
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
11
12
halophenyl group, whether or not further substituted on the indole
12
13
ring to any extent, and whether or not substituted on the phenyl
13
14
ring to any extent. Phenylacetylindoles include, but are not
14
15
limited to:
15
16
a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
16
17
b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
17
18
(RCS-8),
18
19
c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
19
20
d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
20
21
e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
21
22
f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);
22
23
6. Cyclohexylphenols: any compound containing a 2-(3-
23
24
hydroxycyclohexyl)phenol structure with or without substitution at
24
Req. No. 566 Page 23

1
the 5-position of the phenolic ring by an alkyl, haloalkyl,
1
2
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
2
3
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
3
4
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
4
5
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
5
6
phenyl, or halophenyl group, and whether or not further substituted
6
7
on the cyclohexyl ring to any extent. Cyclohexylphenols include,
7
8
but are not limited to:
8
9
a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
9
10
hydroxycyclohexyl]-phenol (CP-47,497),
10
11
b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
11
12
phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
12
13
or
13
14
c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
14
15
hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
15
16
7. Benzoylindoles: any compound containing a 3-(benzoyl)indole
16
17
structure with or without substitution at the nitrogen atom of the
17
18
indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
18
19
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
19
20
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
20
21
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
21
22
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
22
23
halophenyl group, whether or not further substituted on the indole
23
24
ring to any extent, and whether or not substituted on the phenyl
24
Req. No. 566 Page 24

1
group to any extent. Benzoylindoles include, but are not limited
1
2
to:
2
3
a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
3
4
b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
4
5
methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
5
6
c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
6
7
d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
7
8
e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
8
9
iodobenzoyl)indole (AM-2233);
9
10
8. Cyclopropoylindoles: Any compound containing a 3-
10
11
(cyclopropoyl)indole structure with substitution at the nitrogen
11
12
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
12
13
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
13
14
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
14
15
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
15
16
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
16
17
halophenyl group, whether or not further substituted in the indole
17
18
ring to any extent and whether or not substituted in the
18
19
cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
19
20
are not limited to:
20
21
a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
21
22
(UR-144),
22
23
b. 1-(5-chloropentyl)-3-(2,2,3,3-
23
24
tetramethylcyclopropoyl)indole (5Cl-UR-144), or
24
Req. No. 566 Page 25

1
c. 1-(5-fluoropentyl)-3-(2,2,3,3-
1
2
tetramethylcyclopropoyl)indole (XLR11);
2
3
9. Indole Amides: Any compound containing a 1H-Indole-3-
3
4
carboxamide structure with or without substitution at the nitrogen
4
5
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
5
6
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
6
7
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
7
8
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
8
9
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
9
10
halophenyl group, whether or not substituted at the carboxamide
10
11
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
11
12
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
12
13
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
13
14
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
14
15
further substituted in the indole, adamantyl, naphthyl, phenyl,
15
16
pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
16
17
Amides include, but are not limited to:
17
18
a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
18
19
(2NE1),
19
20
b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
20
21
carboxamide (STS-135),
21
22
c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
22
23
indole-3-carboxamide (ADBICA),
23
24
24
Req. No. 566 Page 26

1
d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
1
2
fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
2
3
e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
3
4
(NNE1),
4
5
f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
5
6
carboxamide (5F-NNE1),
6
7
g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
7
8
or
8
9
h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
9
10
(5F-SDB-006);
10
11
10. Indole Esters: Any compound containing a 1H-Indole-3-
11
12
carboxylate structure with or without substitution at the nitrogen
12
13
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
13
14
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
14
15
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
15
16
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
16
17
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
17
18
halophenyl group, whether or not substituted at the carboxylate
18
19
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
19
20
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
20
21
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
21
22
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
22
23
further substituted in the indole, adamantyl, naphthyl, phenyl,
23
24
24
Req. No. 566 Page 27

1
pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
1
2
Esters include, but are not limited to:
2
3
a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
3
4
22),
4
5
b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
5
6
carboxylate (5F-PB-22),
6
7
c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
7
8
carboxylate (BB-22),
8
9
d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
9
10
carboxylate (FDU-PB-22), or
10
11
e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
11
12
carboxylate (NM2201);
12
13
11. Adamantanoylindoles: Any compound containing an
13
14
adamantanyl-(1H-indol-3-yl)methanone structure with or without
14
15
substitution at the nitrogen atom of the indole ring by an alkyl,
15
16
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
16
17
benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
17
18
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
18
19
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
19
20
phenyl, or halophenyl group, whether or not further substituted in
20
21
the indole ring to any extent and whether or not substituted in the
21
22
adamantyl ring to any extent. Adamantanoylindoles include, but are
22
23
not limited to:
23
24
24
Req. No. 566 Page 28

1
a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
1
2
indol-3-yl]methanone (AM1248), or
2
3
b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
3
4
001);
4
5
12. Carbazole Ketone: Any compound containing (9H-carbazole-3-
5
6
yl) methanone structure with or without substitution at the nitrogen
6
7
atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
7
8
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
8
9
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
9
10
2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
10
11
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
11
12
halophenyl group, with substitution at the carbon of the methanone
12
13
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
13
14
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
14
15
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
15
16
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
16
17
further substituted at the carbazole, adamantyl, naphthyl, phenyl,
17
18
pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
18
19
Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-
19
20
9H-carbazol-3-yl)methanone (EG-018);
20
21
13. Benzimidazole Ketone: Any compound containing
21
22
(benzimidazole-2-yl) methanone structure with or without
22
23
substitution at either nitrogen atom of the benzimidazole ring by an
23
24
alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
24
Req. No. 566 Page 29

1
cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-
1
2
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
2
3
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
3
4
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
4
5
halophenyl group, with substitution at the carbon of the methanone
5
6
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
6
7
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
7
8
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
8
9
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
9
10
further substituted in the benzimidazole, adamantyl, naphthyl,
10
11
phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.
11
12
Benzimidazole Ketones include, but are not limited to:
12
13
a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
13
14
l)methanone (JWH-018 benzimidazole analog), or
14
15
b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
15
16
yl)(naphthalen-1-yl)methanone (FUBIMINA); and
16
17
14. Modified by Replacement: any compound defined in this
17
18
subsection that is modified by replacement of a carbon with nitrogen
18
19
in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
19
20
H. Any material, compound, mixture, extract, or preparation
20
21
that contains a prohibited kratom product as provided in subsection
21
22
A of Section 1-1432.4 of this title.
22
23
I. Any prescription drug approved by the federal Food and Drug
23
24
Administration under the provisions of Section 505 of the Federal
24
Req. No. 566 Page 30

1
Food, Drug and Cosmetic Act, Title 21 of the United States Code,
1
2
Section 355, that is designated, rescheduled, or deleted as a
2
3
controlled substance under federal law by the United States Drug
3
4
Enforcement Administration shall be excluded from Schedule I and
4
5
shall be prescribed, distributed, dispensed, or used in accordance
5
6
with federal law upon the issuance of a notice, final rule, or
6
7
interim final rule by the United States Drug Enforcement
7
8
Administration designating, rescheduling, or deleting as a
8
9
controlled substance such a drug product under federal law, unless
9
10
and until the State Board of Pharmacy takes action pursuant to
10
11
Section 2-201 of this title. If the Board of Pharmacy does not take
11
12
action pursuant to Section 2-201 of this title, the drug product
12
13
shall be deemed to be designated, rescheduled, or deleted as a
13
14
controlled substance in accordance with federal law and in
14
15
compliance with the Uniform Controlled Dangerous Substances Act.
15
16
SECTION 2. This act shall become effective November 1, 2025.
16
17
17
18
60-1-566 CN 1/19/2025 5:44:47 AM
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 566 Page 31

[DELETED:  P B W]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P p p e v s o p f]
[DELETED:  P c a s t g p p c a t]
[DELETED:  P t t o]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P 1 1 1 1 1 1 1]
[DELETED:  P 1 1 1 1 1 1 1 1 1 1]
[DELETED:  P 1 1 1 1]
[DELETED:  P 1 1 1 1 1 1]
[DELETED:  P 5 5 5]
[DELETED:  P 1 1 1 1 1 1 1]
[DELETED:  P 1 N N N]
[DELETED:  P N N 1 N N]
[DELETED:  P q q q n n]
[DELETED:  P a a]
[DELETED:  P n (]
[DELETED:  P C 1]